Investment analysts at StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Free Report) in a report issued on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
Shares of Nabriva Therapeutics stock opened at $0.00 on Wednesday. The firm has a market capitalization of $6,403.00, a PE ratio of 0.00 and a beta of 1.53. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.52 and a current ratio of 0.85. Nabriva Therapeutics has a 12 month low of $1.22 and a 12 month high of $8.45.
Nabriva Therapeutics Company Profile
Read More
- Five stocks we like better than Nabriva Therapeutics
- What is the Hang Seng index?
- When Is the Best Time to Invest in Mutual Funds?
- Differences Between Momentum Investing and Long Term Investing
- Is NVIDIA Stock in a Correction or Consolidation?
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.